ATE339417T1 - Biphenyl - sulfonamide als duale angiotensin - endothelin - rezeptor - antagonisten - Google Patents

Biphenyl - sulfonamide als duale angiotensin - endothelin - rezeptor - antagonisten

Info

Publication number
ATE339417T1
ATE339417T1 AT00984282T AT00984282T ATE339417T1 AT E339417 T1 ATE339417 T1 AT E339417T1 AT 00984282 T AT00984282 T AT 00984282T AT 00984282 T AT00984282 T AT 00984282T AT E339417 T1 ATE339417 T1 AT E339417T1
Authority
AT
Austria
Prior art keywords
endothelin
sulfonamide
antagonists
biphenyl
receptor
Prior art date
Application number
AT00984282T
Other languages
English (en)
Inventor
Natesan Murugesan
John E Tellew
John E Macor
Zhengxiang Gu
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE339417T1 publication Critical patent/ATE339417T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C07D261/16—Benzene-sulfonamido isoxazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT00984282T 1999-12-15 2000-12-13 Biphenyl - sulfonamide als duale angiotensin - endothelin - rezeptor - antagonisten ATE339417T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US46403799A 1999-12-15 1999-12-15
US48119700A 2000-01-11 2000-01-11
US51377900A 2000-02-25 2000-02-25
US60432200A 2000-06-26 2000-06-26
US64364000A 2000-08-22 2000-08-22

Publications (1)

Publication Number Publication Date
ATE339417T1 true ATE339417T1 (de) 2006-10-15

Family

ID=27541688

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00984282T ATE339417T1 (de) 1999-12-15 2000-12-13 Biphenyl - sulfonamide als duale angiotensin - endothelin - rezeptor - antagonisten

Country Status (12)

Country Link
EP (2) EP1237888B1 (de)
JP (1) JP2003520785A (de)
AR (1) AR029417A1 (de)
AT (1) ATE339417T1 (de)
AU (1) AU2092601A (de)
CA (1) CA2395088A1 (de)
CO (1) CO5450242A1 (de)
DE (1) DE60030764T2 (de)
ES (1) ES2273739T3 (de)
PE (1) PE20010930A1 (de)
UY (1) UY26482A1 (de)
WO (1) WO2001044239A2 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6639082B2 (en) 2000-10-17 2003-10-28 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
US7507767B2 (en) 2001-02-08 2009-03-24 Schering Corporation Cannabinoid receptor ligands
US7067539B2 (en) 2001-02-08 2006-06-27 Schering Corporation Cannabinoid receptor ligands
DE60222409T2 (de) 2001-05-31 2008-09-25 Vicore Pharma Ab Trizyklische verbindungen, nützlich als angiotensin ii agonisten
AR037352A1 (es) 2001-11-14 2004-11-03 Schering Corp Compuestos ligandos de los receptores de los cannabinoides, una composicion farmaceutica , y el uso de dichos compuestos para la manufactura de medicamentos
EP1443919A4 (de) 2001-11-16 2006-03-22 Bristol Myers Squibb Co Doppelte hemmer des adipozyten-fettsäure-bindungsproteins und des keratinozyten-fettsäure-bindungsproteins
TWI328007B (en) 2002-01-16 2010-08-01 Astrazeneca Ab Novel compounds
EP1539693B9 (de) 2002-06-19 2008-10-08 Schering Corporation Agonisten des cannabinoidrezeptors
GB0219660D0 (en) 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
TW200505902A (en) 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
WO2004085420A1 (en) * 2003-03-24 2004-10-07 Vicore Pharma Ab Bicyclic compounds useful as angiotensin ii agonists
EP1660183A2 (de) * 2003-05-05 2006-05-31 Eli Lilly and Company Behandlung von kardiovaskulären erkrankungen mit einer substanz der formel 1 (cs 747 - prasugrel, rn 150322-43-4)
DE10336497B4 (de) * 2003-08-08 2007-04-05 Freie Universität Berlin Substituierte Pyridine und ein Verfahren zur Herstellung von substituierten Pyridinen
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7700603B2 (en) 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
NZ555334A (en) 2004-12-24 2010-05-28 Spinifex Pharm Pty Ltd Method of treatment or prophylaxis of a neuropathic condition using AT2 receptor antagonist
EP1996588A4 (de) * 2006-03-03 2011-10-05 Torrent Pharmaceuticals Ltd Neue dual-action-rezeptorantagonisten (dara) an den ati- und eta-rezeptoren
WO2007109456A2 (en) * 2006-03-16 2007-09-27 Pharmacopeia, Inc. Substituted biphenyl isoxazole sulfonamides as dual angiotensin endothelin receptor antagonists
JP5230595B2 (ja) * 2006-03-20 2013-07-10 スピニフェクス ファーマシューティカルズ ピーティーワイ リミテッド 炎症性疼痛の治療または予防の方法
AU2012203919B2 (en) * 2006-03-20 2014-10-23 Novartis Ag Method of treatment or prophylaxis of inflammatory pain
MX2009006228A (es) 2006-12-12 2009-06-22 Schering Corp Inhibidores de aspartil proteasa.
TW200838501A (en) * 2007-02-02 2008-10-01 Theravance Inc Dual-acting antihypertensive agents
WO2009155448A1 (en) * 2008-06-20 2009-12-23 Ligand Pharmaceuticals Inc. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
WO2009158309A2 (en) * 2008-06-25 2009-12-30 Ligand Pharmaceuticals Inc. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
GB0815947D0 (en) * 2008-09-02 2008-10-08 Univ Dundee Compounds
WO2010114801A1 (en) * 2009-03-31 2010-10-07 Ligand Pharmaceuticals Inc. Oral formulations of diphenylsulfonamide endothelin and angiotensin ii receptor agonists to treat elevated blood pressure and diabetic nephropathy
US7956054B2 (en) * 2009-07-07 2011-06-07 Theravance, Inc. Dual-acting pyrazole antihypertensive agents
CN104761548B (zh) * 2015-04-27 2017-09-12 梯尔希(南京)药物研发有限公司 一种稳定同位素标记的二苯基磺酰胺类药物的制备方法
JP2019530713A (ja) 2016-10-13 2019-10-24 レトロフィン, インコーポレイテッド 腎臓疾患または障害を処置するためのビフェニルスルホンアミド化合物
US10703723B2 (en) 2017-03-09 2020-07-07 Truly Translational Sweden Ab Prodrugs of sulfasalazine, pharmaceutical compositions thereof and their use in the treatment of autoimmune disease
ES2897200T3 (es) 2017-05-31 2022-02-28 Amplio Pharma Ab Una composición farmacéutica que comprende una combinación de metotrexato y novobiocina, y el uso de la composición en terapia
EP3689870B1 (de) * 2017-09-27 2022-07-13 Kagoshima University Analgetikum unter verwendung eines pac1-rezeptor-antagonisten-arzneimittels
EP3489222A1 (de) 2017-11-23 2019-05-29 medac Gesellschaft für klinische Spezialpräparate mbH Sulfasalazinesalze, herstellungsverfahren und verwendungen
ES2965337T3 (es) 2017-11-23 2024-04-12 Medac Ges Fuer Klinische Spezialpraeparate Mbh Composición farmacéutica para administración oral que contiene sulfasalazina y/o una sal orgánica de sulfasalazina, proceso de producción y uso
JP7524167B2 (ja) 2018-10-04 2024-07-29 トラビア セラピューティクス, インコーポレイテッド Iv型コラーゲン疾患の処置のためのビフェニルスルホンアミド化合物
BR112021012226A2 (pt) * 2018-12-21 2021-09-08 Travere Therapeutics, Inc. Composições de esparsentano amorfo
CN109928897B (zh) * 2019-04-01 2021-09-14 四川大学华西医院 防治梗死性疾病的双胍衍生物及其应用
WO2022266370A1 (en) 2021-06-17 2022-12-22 Aria Pharmaceuticals, Inc. Sparsentan for treating idiopathic pulmonary fibrosis
KR20240051999A (ko) * 2021-08-26 2024-04-22 상하이 한서 바이오메디컬 컴퍼니 리미티드 방향족 고리 함유 생물학적 길항제, 이의 제조 방법 및 용도
US20240417395A1 (en) * 2021-10-21 2024-12-19 Nicoya Therapeutics (Shanghai) Co., Ltd Dual antagonist and use thereof
WO2023127853A1 (ja) * 2021-12-28 2023-07-06 株式会社アークメディスン 化合物、アンジオテンシンiiタイプ1受容体拮抗剤及び医薬組成物
CN115636799A (zh) * 2022-11-04 2023-01-24 苏州莱安医药化学技术有限公司 一种双效内皮素-血管紧张素受体拮抗剂的制备方法
JP2026508235A (ja) * 2023-02-24 2026-03-10 江▲蘇▼豪森▲薬▼▲業▼集▲団▼有限公司 芳香環含有誘導体アンタゴニストの塩、その製造方法及び応用
IT202400000246A1 (it) * 2024-01-09 2025-07-09 Procos Spa Processo per la preparazione di sparsentan
WO2026021516A1 (zh) * 2024-07-25 2026-01-29 深圳信立泰药业股份有限公司 一种取代的血管紧张肽和内皮肽受体拮抗剂及其应用
WO2026067819A1 (zh) * 2024-09-30 2026-04-02 江苏豪森药业集团有限公司 含芳环类生物拮抗剂在制备治疗或预防肾脏疾病药物中的应用
CN119462631A (zh) * 2024-10-09 2025-02-18 广东莱佛士制药技术有限公司 一种司巴生坦中间体的合成方法
CN120289447A (zh) * 2025-06-11 2025-07-11 成都臻拓医药科技有限公司 一种司帕生坦的晶型及其制备方法、药物组合物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260328A (en) * 1989-04-06 1993-11-09 Farmitalia Carlo Erba Srl Phenyl-indenopurazol 3-oxo-propanamide derivatives useful in the treatment of rheumatoid arthritis
EP0443983B1 (de) * 1990-02-19 1996-02-28 Ciba-Geigy Ag Acylverbindungen
US5260325A (en) * 1991-08-19 1993-11-09 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking tertiary amides
GB2264710A (en) * 1992-03-04 1993-09-08 Merck & Co Inc Quinoline and azaquinoline angiotensin ii antagonists incorporating a substituted biphenyl element
US5514696A (en) * 1992-05-06 1996-05-07 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
NZ247440A (en) * 1992-05-06 1995-04-27 Squibb & Sons Inc Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof
AU675660B2 (en) * 1992-07-17 1997-02-13 Merck & Co., Inc. Substituted biphenylmethylimidazopyridines
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5760038A (en) * 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5780473A (en) * 1995-02-06 1998-07-14 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
AU6108596A (en) * 1995-06-15 1997-01-15 Merck & Co., Inc. Polymorphic forms of an angiotensin ii antagonist
GB9512697D0 (en) * 1995-06-22 1995-08-23 Zeneca Ltd Heterocyclic compounds
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
ID26984A (id) * 1998-07-06 2001-02-22 Bristol Myers Squibb Co Senyawa-senyawa sulfonamida sebagai antagonis reseptor angiotensin endotelin ganda

Also Published As

Publication number Publication date
JP2003520785A (ja) 2003-07-08
EP1741713A2 (de) 2007-01-10
EP1237888B1 (de) 2006-09-13
CO5450242A1 (es) 2004-10-29
UY26482A1 (es) 2001-07-31
EP1741713A3 (de) 2009-09-09
DE60030764T2 (de) 2007-09-13
EP1237888A2 (de) 2002-09-11
PE20010930A1 (es) 2001-11-18
AR029417A1 (es) 2003-06-25
DE60030764D1 (de) 2006-10-26
CA2395088A1 (en) 2001-06-21
AU2092601A (en) 2001-06-25
ES2273739T3 (es) 2007-05-16
WO2001044239A3 (en) 2001-11-01
WO2001044239A2 (en) 2001-06-21

Similar Documents

Publication Publication Date Title
DE60030764D1 (de) Biphenyl - sulfonamide als duale angiotensin - endothelin - rezeptor - antagonisten
NO20016115D0 (no) Substituerte heterocykelkondenserte gamma-karboliner
PT1224180E (pt) Azois substituidos
DE60134094D1 (de) C7-taxanester als antitumormittel
DE60011764D1 (de) Werkstoffsprüfung
SE0002096A0 (sv) Avgasrecirkuleringssystem
NO331011B1 (no) Hoyytelsesdatakabel
DE69932949D1 (de) Aufszugssteuerung
DE60002808D1 (de) Propellerrotornabe
DK1190020T3 (da) Celluligninbrændstof
DE50009570D1 (de) Wechselcorrugator
DE60001894D1 (de) Busschienenverbindungsstruktur
DE59909346D1 (de) Zylinderkopfdichtung
DE60040745D1 (de) Viertorhybrid
DE69924240D1 (de) Ladungsträgerteilchenstrahlvorrichtung
DE50011908D1 (de) 16-hydroxyestratriene als selektiv wirksame estrogene
DE60025623D1 (de) Bohrmeisselverbinder
DE60003072D1 (de) Thiazolidindion-derivate als antidiabetika
DE50012482D1 (de) Tibiamarknagel
DE60013238D1 (de) Klingenabstreifanordnung
DE60020201D1 (de) Koaxialkabelherstellungsverfahren
DE50003660D1 (de) Diacylhydrazinderivate
NO20022927L (no) Substituerte pyrrazoler
DE60027753D1 (de) Kompositnadel
DE19983890T1 (de) Ventiltaktgebungsjustiereinrichtung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties